BSD Medical receives notice of allowance for new patentNanion Technologies GmbH, a supplier of automated, parallel patch-clamp systems based in Munich, Germany, has announced that they would appeal the decision of the European Patent Office (EPO) to uphold tHeska Corporation has announced that it has completed the sale of its rights in a worldwide patent portfolio covering a number of major allergens and the genes that encode them to Access Pharmaceuticals, Inc has announced that the Company has received a "Notice of Allowance" letter from the United States Patent and Trademark Office for its patent application entitled "LiquNano Chemical Systems announced today that it has filed a US Patent application on a breakthrough new material that exhibits light (luminescent) in the absence of heat. This Nano-enhanced Ranbaxy Laboratories Limited announced that the Federal Court of Canada has handed down a favorable decision in the company's case against Pfizer by finding invalid Pfizer's Canadian atorvastatin pateThai Public Health Minister Mongkol Songkhla plans to break patents on an antiretroviral drug and a drug for heart disease by issuing compulsory licenses to produce lower-cost versions, Access Pharmaceuticals, Inc. announced today that it was issued U.S. Patent No. 7,166,733 by the U.S. Patent and Trademark Office. This patent, entitled "O,O'-Amidomalonato and N,O-AmidomArchus Orthopedics, Inc. has announced that the European Patent Office has confirmed the validity of its patent number EP-B-1223872 following an Opposition that concluded with oral proceedings on JaNventa Biopharmaceuticals has announced that the U.S. Patent and Trademark Office has issued Patent Number 7,157,089 to Nventa.The patent provides coverage for compositions of fusion proteinThe Swiss pharmaceutical giant Novartis is in court in India this week challenging the country's patent laws.The drug company is attempting to overturn the Indian government's rejection of itBSD Medical receives notice of allowance for new patentBSD Medical today announced that the company has received "official notice of allowance" for a new patent that is expected to be issued by the U.S. Patent Office. The patent is being secured as the basis for a new disposable device that would enable the use of simultaneous brachytherapy (interstitial radiation) and microwave hyperthermia therapy, employing BSD's existing systems. Current technology allows only sequential treatments. According to research with a breast cancer model, when hyperthermia therapy (a thermal treatment for cancer) was administered simultaneously with radiation, the effective dose of radiation (thermal enhancement) was maximized -- amplified 2.5 times, without increasing toxicity (Overgaard, Int. J. Radiation. Onc. Biol Phys., Vol 6, No 11). The idea is to get much more out of radiation treatments without adding side effects. "The new device is intended to optimize the effectiveness of an already powerful therapy," according to Paul F. Turner, Chairman and Chief Technology Officer of BSD. "The treatment can be provided through a convenient disposable," Turner added.The American Cancer Society's journal, CANCER, and the International Journal of Radiation Oncology Biology Physics by the American Society for Therapeutic Radiology and Oncology (ASTRO) have both published clinical trials demonstrating the therapeutic enhancement achieved by the addition of interstitial hyperthermia therapy to brachytherapy. Among the institutions that have published in support of the efficacy of these combined therapies are UCSF and Johns Hopkins Hospital.Certain cancers are best approached through interstitial radiation therapy so that the treatment can be delivered locally within the tumor, limiting potential radiation damage to surrounding normal tissue. BSD Medical has the rights of all of the FDA approvals that have thus far been issued for combining interstitial microwave hyperthermia therapy with brachytherapy in treatment./&& 2006, , All Rights Reserved.Access denied | www.news-medical.net used Cloudflare to restrict access
Please enable cookies.
What happened?
The owner of this website (www.news-medical.net) has banned your access based on your browser's signature (780e-ua98).Request full-text
Do you want to read the rest of this article?
CitationsCitations0ReferencesReferences0ArticleArticleArticleArticleData provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.This publication is from a journal that may support self archiving.U.S. patent office issues notice of allowance for patent application related to ctis glycopolymer technology}